EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex

Sam Strickson iD, Kirsty F Houslay, Victor A Negri, Yoichiro Ohne iD, Tomas Ottosson, Roger B Dodd iD, Catherine Chaillan Huntington, Tina Baker, Jingjing Li, Katherine E Stephenson, Andy J O'Connor, J Sophie Sagawe iD und 16 weitere

European Respiratory Journal · 2023-09 · 62 (3) · 2202210

DOI: 10.1183/13993003.02210-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 13.07.2023. Verfasst von Sam Strickson und 27 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Interleukin-33, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epithelial damage, repair and remodelling are critical features of chronic airway diseases including chronic obstructive pulmonary disease (COPD). Interleukin (IL)-33 released from damaged airway epithelia causes inflammation via its receptor, serum stimulation-2 (ST2). Oxidation of IL-33 to a non-ST2-binding form (IL-33 ox ) is thought to limit its activity. We investigated whether IL-33 ox has functional activities that are independent of ST2 in the airway epithelium.

Methods

In vitro epithelial damage assays and three-dimensional, air–liquid interface (ALI) cell culture models of healthy and COPD epithelia were used to elucidate the functional role of IL-33 ox . Transcriptomic changes occurring in healthy ALI cultures treated with IL-33 ox and COPD ALI cultures treated with an IL-33-neutralising antibody were assessed with bulk and single-cell RNA sequencing analysis.

Results

We demonstrate that IL-33 ox forms a complex with receptor for advanced glycation end products (RAGE) and epidermal growth factor receptor (EGFR) expressed on airway epithelium. Activation of this alternative, ST2-independent pathway impaired epithelial wound closure and induced airway epithelial remodelling in vitro . IL-33 ox increased the proportion of mucus-producing cells and reduced epithelial defence functions, mimicking pathogenic traits of COPD. Neutralisation of the IL-33 ox pathway reversed these deleterious traits in COPD epithelia. Gene signatures defining the pathogenic effects of IL-33 ox were enriched in airway epithelia from patients with severe COPD.

Conclusions

Our study reveals for the first time that IL-33, RAGE and EGFR act together in an ST2-independent pathway in the airway epithelium and govern abnormal epithelial remodelling and muco-obstructive features in COPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Pulmonary Disease, Chronic ObstructiveHumansEpithelial CellsErbB ReceptorsInterleukin-1 Receptor-Like 1 ProteinOxidation-ReductionReceptor for Advanced Glycation End Products

Substanzen

EGFR protein, humanErbB ReceptorsIL1RL1 protein, humanIL33 protein, humanInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Receptor for Advanced Glycation End ProductsAGER protein, human

Autor:innen und Institutionen

  • Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • These authors contributed equally to this work.
  • Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Sam Strickson, Yoichiro Ohne, Roger B Dodd, J Sophie Sagawe, Jonas S Erjefält

Förderung

  • AstraZeneca

Zitieren

APA

Strickson, S., Houslay, K. F., Negri, V. A., Ohne, Y., Ottosson, T., Dodd, R. B., Huntington, C. C., Baker, T., Li, J., Stephenson, K. E., O'Connor, A. J., Sagawe, J. S., Killick, H., Moore, T., Rees, D. G., Koch, S., Sanden, C., Wang, Y., Gubbins, E., …, & Cohen, E. S. (2023). Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex. European Respiratory Journal, 62(3), 2202210. https://doi.org/10.1183/13993003.02210-2022

Vancouver

Strickson S, Houslay KF, Negri VA, Ohne Y, Ottosson T, Dodd RB, et al. Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex. European Respiratory Journal. 2023;62(3):2202210. doi:10.1183/13993003.02210-2022

BibTeX
@article{Strickson2023,
  author = {Strickson, Sam and Houslay, Kirsty F and Negri, Victor A and Ohne, Yoichiro and Ottosson, Tomas and Dodd, Roger B and Huntington, Catherine Chaillan and Baker, Tina and Li, Jingjing and Stephenson, Katherine E and O'Connor, Andy J and Sagawe, J Sophie and Killick, Helen and Moore, Tom and Rees, D Gareth and Koch, Sofia and Sanden, Caroline and Wang, Yixin and Gubbins, Elise and Ghaedi, Mahboobe and Kolbeck, Roland and Saumyaa, Saumyaa and Erjefält, Jonas S and Sims, Gary P and Humbles, Alison A and Scott, Ian C and Romero Ros, Xavier and Cohen, E Suzanne},
  title = {Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {3},
  pages = {2202210},
  doi = {10.1183/13993003.02210-2022}
}
Kostenlos starten →